Skip to main content
SpringerLink
Log in

Nondialytic Supportive Management of AKI

  • Chapter
  • First Online:
Acute Kidney Injury and Regenerative Medicine

  • 600 Accesses

Abstract

Acute kidney injury (AKI) is associated with serious complications such as lethal arrhythmia, lung edema, and electrolyte disorder. For the management of AKI, it is imperative to identify and remove the cause of AKI. Also, it is essential to create a non-damaging environment for kidneys such as non-nephrotoxic drugs, appropriate intravascular volume, and drug dose adjustment. So far, many randomized controlled trials have examined the AKI prevention or treatment effect of various interventions, e.g., dopamine, diuretics, and natriuretic peptide. While most of those interventions did not have a decisive impact on clinical practices, some of them can be beneficial in a limited situation. Further research is expected in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Murugan R, Kellum JA. Acute kidney injury: what’s the prognosis? Nat Rev Nephrol. 2011;7(4):209–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Mohsenin V. Practical approach to detection and management of acute kidney injury in critically ill patient. J Intensive Care. 2017;5:57.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Group KAW. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.

    Google Scholar 

  4. Choudhury D, Ahmed Z. Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2006;2(2):80–91.

    Article  CAS  PubMed  Google Scholar 

  5. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304–77.

    Article  PubMed  Google Scholar 

  6. Nishida O, Ogura H, Egi M, Fujishima S, Hayashi Y, Iba T, Imaizumi H, Inoue S, Kakihana Y, Kotani J, et al. The Japanese clinical practice guidelines for management of sepsis and septic shock 2016 (J-SSCG 2016). J Intensive Care. 2018;6:7.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Post EH, Vincent JL. Renal autoregulation and blood pressure management in circulatory shock. Crit Care. 2018;22(1):81.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Asfar P, Meziani F, Hamel J-F, Grelon F, Megarbane B, Anguel N, Mira J-P, Dequin P-F, Gergaud S, Weiss N, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370(17):1583–93.

    Article  CAS  PubMed  Google Scholar 

  9. Hiragi S, Yamada H, Tsukamoto T, Yoshida K, Kondo N, Matsubara T, Yanagita M, Tamura H, Kuroda T. Acetaminophen administration and the risk of acute kidney injury: a self-controlled case series study. Clin Epidemiol. 2018;10:265–76.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Janssen BJ, Struyker-Boudier HA, Smits JF. Acute arteriolar vasoconstriction following furosemide in conscious spontaneously hypertensive rats. Eur J Pharmacol. 1989;170(1–2):1–9.

    Article  CAS  PubMed  Google Scholar 

  11. Gerber JG, Nies AS. Furosemide-induced vasodilation: importance of the state of hydration and filtration. Kidney Int. 1980;18(4):454–9.

    Article  CAS  PubMed  Google Scholar 

  12. Kantariia VA, Timirbulatov RA, Dvoinikova EV. [Mechanism of the therapeutic effect of furosemide and mannitol in hemorrhagic shock and developing acute renal insufficiency]. Farmakol Toksikol. 1979;42(1):47–51.

    Google Scholar 

  13. Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. Anaesthesia. 2010;65(3):283–93.

    Article  CAS  PubMed  Google Scholar 

  14. Bagshaw SM, Gibney RTN, Kruger P, Hassan I, McAlister FA, Bellomo R. The effect of low-dose furosemide in critically ill patients with early acute kidney injury: a pilot randomized blinded controlled trial (the SPARK study). J Crit Care. 2017;42:138–46.

    Article  CAS  PubMed  Google Scholar 

  15. National Institute for Health and Clinical Excellence: Guidance. NICE clinical guideline 169: acute kidney injury: prevention, detection and management of acute kidney injury up to the point of renal replacement therapy; 2013.

    Google Scholar 

  16. Doi K, Nishida O, Shigematsu T, Sadahiro T, Itami N, Iseki K, Yuzawa Y, Okada H, Koya D, Kiyomoto H, et al. The Japanese clinical practice guideline for acute kidney injury 2016. J Intensive Care. 2018;6:48.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Yang B, Xu J, Xu F, Zou Z, Ye C, Mei C, Mao Z. Intravascular administration of mannitol for acute kidney injury prevention: a systematic review and meta-analysis. PLoS One. 2014;9(1):e85029.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  18. Costello JM, Dunbar-Masterson C, Allan CK, Gauvreau K, Newburger JW, McGowan FX Jr, Wessel DL, Mayer JE Jr, Salvin JW, Dionne RE, et al. Impact of empiric nesiritide or milrinone infusion on early postoperative recovery after Fontan surgery: a randomized, double-blind, placebo-controlled trial. Circ Heart Fail. 2014;7(4):596–604.

    Article  CAS  PubMed  Google Scholar 

  19. Denton MD, Chertow GM, Brady HR. “Renal-dose” dopamine for the treatment of acute renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. 1996;50(1):4–14.

    Article  CAS  PubMed  Google Scholar 

  20. Pichler M, Kleinberger G, Kotzaurek R, Pall H, Szeless S. [Clinical results with dopamine in acute renal failure (author’s transl)]. Wien Klin Wochenschr. 1976;88(2):72–74.

    Google Scholar 

  21. Steinhausen M, Weis S, Fleming J, Dussel R, Parekh N. Responses of in vivo renal microvessels to dopamine. Kidney Int. 1986;30(3):361–70.

    Article  CAS  PubMed  Google Scholar 

  22. Olsen NV, Hansen JM, Ladefoged SD, Fogh-Andersen N, Leyssac PP. Renal tubular reabsorption of sodium and water during infusion of low-dose dopamine in normal man. Clin Sci (Lond). 1990;78(5):503–7.

    Article  CAS  Google Scholar 

  23. Carcoana OV, Hines RL. Is renal dose dopamine protective or therapeutic? Yes. Crit Care Clin. 1996;12(3):677–85.

    Article  CAS  PubMed  Google Scholar 

  24. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142(7):510–24.

    Article  CAS  PubMed  Google Scholar 

  25. Schmoelz M, Schelling G, Dunker M, Irlbeck M. Comparison of systemic and renal effects of dopexamine and dopamine in norepinephrine-treated septic shock. J Cardiothorac Vasc Anesth. 2006;20(2):173–8.

    Article  CAS  PubMed  Google Scholar 

  26. Triposkiadis FK, Butler J, Karayannis G, Starling RC, Filippatos G, Wolski K, Parissis J, Parisis C, Rovithis D, Koutrakis K, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the dopamine in acute decompensated heart failure II (DAD-HF II) trial. Int J Cardiol. 2014;172(1):115–21.

    Article  PubMed  Google Scholar 

  27. Lauschke A, Teichgraber UK, Frei U, Eckardt KU. ‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int. 2006;69(9):1669–74.

    Article  CAS  PubMed  Google Scholar 

  28. De Backer D, Aldecoa C, Njimi H, Vincent JL. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis∗. Crit Care Med. 2012;40(3):725–30.

    Article  CAS  PubMed  Google Scholar 

  29. Link Mark S, Berkow Lauren C, Kudenchuk Peter J, Halperin Henry R, Hess Erik P, Moitra Vivek K, Neumar Robert W, O’Neil Brian J, Paxton James H, Silvers Scott M, et al. Part 7: adult advanced cardiovascular life support. Circulation. 2015;132(18_suppl_2):S444–64.

    Article  CAS  PubMed  Google Scholar 

  30. Brogden RN, Markham A. Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs. 1997;54(4):634–50.

    Article  CAS  PubMed  Google Scholar 

  31. Singer I, Epstein M. Potential of dopamine A-1 agonists in the management of acute renal failure. Am J Kidney Dis. 1998;31(5):743–55.

    Article  CAS  PubMed  Google Scholar 

  32. Zangrillo A, Biondi-Zoccai GG, Frati E, Covello RD, Cabrini L, Guarracino F, Ruggeri L, Bove T, Bignami E, Landoni G. Fenoldopam and acute renal failure in cardiac surgery: a meta-analysis of randomized placebo-controlled trials. J Cardiothorac Vasc Anesth. 2012;26(3):407–13.

    Article  CAS  PubMed  Google Scholar 

  33. Landoni G, Biondi-Zoccai GG, Tumlin JA, Bove T, De Luca M, Calabro MG, Ranucci M, Zangrillo A. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis. 2007;49(1):56–68.

    Article  CAS  PubMed  Google Scholar 

  34. Gillies MA, Kakar V, Parker RJ, Honore PM, Ostermann M. Fenoldopam to prevent acute kidney injury after major surgery-a systematic review and meta-analysis. Crit Care. 2015;19:449.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Sun H, Xie Q, Peng Z. Does fenoldopam protect kidney in cardiac surgery? A systemic review and meta-analysis with trial sequential analysis. Shock. 2019;52(3):326–33.

    Article  CAS  PubMed  Google Scholar 

  36. Tumlin JA, Finkel KW, Murray PT, Samuels J, Cotsonis G, Shaw AD. Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. Am J Kidney Dis. 2005;46(1):26–34.

    Article  CAS  PubMed  Google Scholar 

  37. Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, et al. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA. 2014;312(21):2244–53.

    Article  PubMed  CAS  Google Scholar 

  38. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. Endocr Rev. 2006;27(1):47–72.

    Article  CAS  PubMed  Google Scholar 

  39. Kuwahara K, Nakao K. Regulation and significance of atrial and brain natriuretic peptides as cardiac hormones. Endocr J. 2010;57(7):555–65.

    Article  CAS  PubMed  Google Scholar 

  40. Boerrigter G, Burnett JC Jr. Natriuretic peptides renal protective after all? J Am Coll Cardiol. 2011;58(9):904–6.

    Article  CAS  PubMed  Google Scholar 

  41. Rahman SN, Kim GE, Mathew AS, Goldberg CA, Allgren R, Schrier RW, Conger JD. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int. 1994;45(6):1731–8.

    Article  CAS  PubMed  Google Scholar 

  42. Allgren RL, Marbury TC, Rahman SN, Weisberg LS, Fenves AZ, Lafayette RA, Sweet RM, Genter FC, Kurnik BR, Conger JD, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med. 1997;336(12):828–34.

    Article  CAS  PubMed  Google Scholar 

  43. Lewis J, Salem MM, Chertow GM, Weisberg LS, McGrew F, Marbury TC, Allgren RL. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis. 2000;36(4):767–74.

    Article  CAS  PubMed  Google Scholar 

  44. Yamada H, Doi K, Tsukamoto T, Kiyomoto H, Yamashita K, Yanagita M, Terada Y, Mori K. Low-dose atrial natriuretic peptide for prevention or treatment of acute kidney injury: a systematic review and meta-analysis. Crit Care. 2019;23(1):41.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA. 2005;293(15):1900–5.

    Article  CAS  PubMed  Google Scholar 

  46. Xiong B, Wang C, Yao Y, Huang Y, Tan J, Cao Y, Zou Y, Huang J. The dose-dependent effect of nesiritide on renal function in patients with acute decompensated heart failure: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2015;10(6):e0131326.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Gong B, Wu Z, Li Z. Efficacy and safety of nesiritide in patients with decompensated heart failure: a meta-analysis of randomised trials. BMJ Open. 2016;6(1):e008545.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Mitaka C, Kudo T, Haraguchi G, Tomita M. Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis. Crit Care. 2011;15(5):R258.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Zhou CC, Yao WT, Ge YZ, Xu LW, Wu R, Gao XF, Song KW, Jiang XM, Wang M, Huang WJ, et al. Remote ischemic conditioning for the prevention of contrast-induced acute kidney injury in patients undergoing intravascular contrast administration: a meta-analysis and trial sequential analysis of 16 randomized controlled trials. Oncotarget. 2017;8(45):79323–36.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar S, Knight R, Kunst G, Laing C, Nicholas J, et al. Remote ischemic preconditioning and outcomes of cardiac surgery. N Engl J Med. 2015;373(15):1408–17.

    Article  CAS  PubMed  Google Scholar 

  51. Le Page S, Prunier F. Remote ischemic conditioning: current clinical perspectives. J Cardiol. 2015;66(2):91–6.

    Article  PubMed  Google Scholar 

  52. Menting TP, Wever KE, Ozdemir-van Brunschot DM, Van der Vliet DJ, Rovers MM, Warle MC. Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury. Cochrane Database Syst Rev. 2017;3:CD010777.

    PubMed  Google Scholar 

  53. Kim TK, Min JJ, Cho YJ, Hausenloy DJ, Ahn H, Kim KH, Hwang HY, Hong DM, Jeon Y. Effects of delayed remote ischemic preconditioning on peri-operative myocardial injury in patients undergoing cardiac surgery—a randomized controlled trial. Int J Cardiol. 2017;227:511–5.

    Article  PubMed  Google Scholar 

  54. Song JW, Lee WK, Lee S, Shim JK, Kim HJ, Kwak YL. Remote ischaemic conditioning for prevention of acute kidney injury after valvular heart surgery: a randomised controlled trial. Br J Anaesth. 2018;121(5):1034–40.

    Article  CAS  PubMed  Google Scholar 

  55. Diamantis E, Troupis T, Mazarakis A, Kyriakos G, Diamanti S, Troupis G, Skandalakis P. Primary and secondary prevention of acute coronary syndromes: the role of the statins. Recent Adv Cardiovasc Drug Discov. 2014;9(2):97–105.

    Article  CAS  PubMed  Google Scholar 

  56. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005;4(12):977–87.

    Article  CAS  PubMed  Google Scholar 

  57. Park JH, Shim JK, Song JW, Soh S, Kwak YL. Effect of atorvastatin on the incidence of acute kidney injury following valvular heart surgery: a randomized, placebo-controlled trial. Intensive Care Med. 2016;42(9):1398–407.

    Article  CAS  PubMed  Google Scholar 

  58. Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ. High-dose perioperative atorvastatin and acute kidney injury following cardiac surgery: a randomized clinical trial. JAMA. 2016;315(9):877–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, et al. Perioperative rosuvastatin in cardiac surgery. N Engl J Med. 2016;374(18):1744–53.

    Article  CAS  PubMed  Google Scholar 

  60. Zhao BC, Shen P, Liu KX. Perioperative statins do not prevent acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth. 2017;31(6):2086–92.

    Article  CAS  PubMed  Google Scholar 

  61. Xiong B, Nie D, Cao Y, Zou Y, Yao Y, Qian J, Rong S, Huang J. Preoperative statin treatment for the prevention of acute kidney injury in patients undergoing cardiac surgery: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2017;26(11):1200–7.

    Article  PubMed  Google Scholar 

  62. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, Manzone C, Amato M, Bellandi F. Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. Am J Cardiol. 2010;105(3):288–92.

    Article  CAS  PubMed  Google Scholar 

  63. Wang N, Qian P, Yan TD, Phan K. Periprocedural effects of statins on the incidence of contrast-induced acute kidney injury: a systematic review and trial sequential analysis. Int J Cardiol. 2016;206:143–52.

    Article  PubMed  Google Scholar 

  64. Marenzi G, Cosentino N, Werba JP, Tedesco CC, Veglia F, Bartorelli AL. A meta-analysis of randomized controlled trials on statins for the prevention of contrast-induced acute kidney injury in patients with and without acute coronary syndromes. Int J Cardiol. 2015;183:47–53.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Kyoto University, Graduate School of Medicine, Kyoto, Japan

    Hiroyuki Yamada

  2. Department of Primary Care and Emergency Medicine, Kyoto University, Graduate School of Medicine, Kyoto, Japan

    Hiroyuki Yamada

Authors
  1. Hiroyuki Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroyuki Yamada .

Editor information

Editors and Affiliations

  1. Department of Endocrinology, Metabolism, and Nephrology, Kochi Medical School, Kochi University, Nankoku, Kochi, Japan

    Yoshio Terada

  2. Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan

    Takashi Wada

  3. Department of Acute Medicine, The University of Tokyo, Tokyo, Japan

    Kent Doi

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yamada, H. (2020). Nondialytic Supportive Management of AKI. In: Terada, Y., Wada, T., Doi, K. (eds) Acute Kidney Injury and Regenerative Medicine . Springer, Singapore. https://doi.org/10.1007/978-981-15-1108-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-981-15-1108-0_16

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-15-1107-3

  • Online ISBN: 978-981-15-1108-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation